PT-141 (Bremelanotide) – Kodiac biolabs

Plain-language summaryIntrigue 72 / 100

PT-141 (bremelanotide), sold as Vyleesi, is a synthetic peptide approved by the FDA for hypoactive sexual desire disorder in premenopausal women. It activates melanocortin receptors in the brain that regulate sexual response. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

52/100

FDA-approved MC4R agonist with real clinical validation but fading novelty and modest effect size

Look, PT-141 is a genuinely interesting compound, just not for the reasons most people think it is. The interesting part isnt the sexual function application per se, its the broader implication: that a cyclic heptapeptide hitting MC4R in the CNS can produce meaningful behavioral effects through dopaminergic and oxytocinergic downstream signaling. That mechanism story, traced from the serendipitous observation of arousal effects during early melanotan II sunless-tanning trials, is one of the more entertaining pivots in peptide pharmacology. Palatin Technologies ran with it for two decades and got an approved drug. Thats real.

The evidence base is genuinely solid by peptide standards. The RECONNECT-1 and RECONNECT-2 trials were phase 3, randomized, placebo-controlled, and they got Vyleesi through the FDA in 2019 with a 1.75 mg subcutaneous dose. On the evidence axis, PT-141 outscores most of the peptide library, which leans heavily on single-lab preclinical work. Here you have actual RCT data in humans with a replicated endpoint. The translational signal is real.

What tempers our enthusiasm is the effect size and the side-effect profile. The RECONNECT trials showed statistically significant improvements in satisfying sexual events and desire scores, but the absolute improvement was modest and the dropout-from-adverse-events number was notable, driven primarily by nausea. The FDA required a boxed warning about blood pressure changes. That limits the translational signal score from reaching the high end. We also cant ignore that flibanserin (Addyi) hit a related space via 5-HT1A agonism and 5-HT2A antagonism before PT-141 did, so the idea of a CNS-mediated HSDD treatment wasnt invented here, even if the mechanism is distinct.

On novelty, the compound has been in the literature since the late 1990s via the melanotan lineage and the MC4R mechanism in sexual behavior has been thoroughly dissected across many labs. By 2026 this isnt a fresh area of inquiry. Where PT-141 retains real bench utility is as a pharmacological probe for the melanocortin system more broadly, specifically MC4R, which sits at an interesting intersection of energy homeostasis, pain modulation, inflammation, and behavior. Researchers investigating that intersection have a clean, selective, FDA-approved probe with well-characterized PK. That matters.

We think this sits solidly in the established-active bucket. Its not a compound you’d build a research program around from scratch today, but it’s a legitimate tool if your program already touches the melanocortin axis or CNS peptide pharmacology. The evidence quality is the strongest argument for it. The novelty deficit is the strongest argument against spending your next grant cycle here.

Novelty: 38
Mechanism promise: 50
In-category differentiation: 55
Evidence quality: 62
Translational signal: 60
Research bench value: 50

Rationale PT-141 earns legitimacy from its 2019 FDA approval and two randomized controlled trials, but seven years post-approval the melanocortin-4 mechanism is well-characterized and the effect size data is sobering; it sits comfortably in established-active territory, differentiated from PDE5 inhibitors and flibanserin by mechanism but no longer a frontier target.

Melanocortin-4 receptor agonist

A FDA-approved (2019) melanocortin receptor agonist (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, derived from melanotan II.

Abstract

Bremelanotide (Vyleesi; PT-141; CAS 189691-06-3; molecular formula C50H68N14O10; molecular weight 1025.18) is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound is derived from the alpha-MSH analog melanotan II by structural modification that increased selectivity toward MC4 versus MC1 (reducing the skin pigmentation activity prominent in melanotan II). PT-141 was originally developed as a sunless tanning agent before pivoting to sexual function applications when central effects were observed. Mechanism is melanocortin-4 receptor agonism in the central nervous system, with downstream effects on dopaminergic and oxytocinergic pathways implicated in sexual response. The compound is administered subcutaneously prior to anticipated sexual activity. Approved dose is 1.75 mg subcutaneous prior to use. Pharmacokinetics: plasma half-life approximately 2.7 hours; the central effect persists 4 to 6 hours after administration. Adverse events include nausea (highest frequency), hyperpigmentation with chronic use, and modest blood pressure elevation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-091Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.